Connection

Besim Ogretmen to Multiple Myeloma

Back to Details
This is a "connection" page, showing publications Besim Ogretmen has written about Multiple Myeloma.
Besim Ogretmen
Connection Strength
0.303
Multiple Myeloma
  1. Phase I study of opaganib, an oral sphingosine kinase 2-specific inhibitor, in relapsed and/or refractory multiple myeloma. Ann Hematol. 2023 Feb; 102(2):369-383.
    View in: PubMed
    Score: 0.194
  2. Inhibition of sphingosine kinase 2 downregulates the expression of c-Myc and Mcl-1 and induces apoptosis in multiple myeloma. Blood. 2014 Sep 18; 124(12):1915-25.
    View in: PubMed
    Score: 0.110
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.